AACR21 roundup: Arcus rolls out PhI data on adenosine blocker for CRC; Codiak's engineered exosome for IL-12 shows early promise
Arcus Biosciences’ adenosine blocker etrumadenant showed some benefit in extending patients’ lives as part of a Phase I/Ib trial in third-line-or-later colorectal cancer patients, according to data presented Saturday at the virtual AACR annual meeting.
Etrumadenant, a dual adenosine A2aR/A2b receptor antagonist, is designed to inhibit adenosine’s role in preventing lympocytes like CD8+ effector T cells and NK cells from infiltrating the tumor microenvironment, the company said. A combination of etrumadenant and chemotherapy regimen FOLFOX-6 posted a median PFS of 4.2 months, a median OS of 13.6 months and an objective response rate of 9.1%. The drug showed consistent benefits in BRAF/RAS mutated cancer cells, the company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.